GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » 10-Year Share Buyback Ratio

CNBX (CNBX Pharmaceuticals) 10-Year Share Buyback Ratio : -34.70% (As of May. 2025)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals 10-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. CNBX Pharmaceuticals's current 10-Year Share Buyback Ratio was -34.70%.

CNBX's 10-Year Share Buyback Ratio is ranked worse than
79.72% of 651 companies
in the Biotechnology industry
Industry Median: -11.7 vs CNBX: -34.70

Competitive Comparison of CNBX Pharmaceuticals's 10-Year Share Buyback Ratio

For the Biotechnology subindustry, CNBX Pharmaceuticals's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CNBX Pharmaceuticals's 10-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's 10-Year Share Buyback Ratio falls into.


;
;

CNBX Pharmaceuticals 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

CNBX Pharmaceuticals (OTCPK:CNBX) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

CNBX Pharmaceuticals 10-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's 10-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » 10-Year Share Buyback Ratio
Comparable Companies
RZONF KRBPQ GBLX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX INSM HKSE:01801 SMMT RPRX XKRX:196170 INCY HKSE:02269
Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
Website
https://www.cnbxpharma.com
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary